Side effects of desmopressin in patients with bleeding disorders

Haemophilia

Volumn 22, Issue 1, 2016, Pages 39-45

  Stoof, S C M ^a   Cnossen, M H ^b   de Maat, M P M ^a   Leebeek, F W G ^a   Kruip, M J H A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Desmopressin; Haemophilia; Side effects; Von Willebrand disease

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; DESMOPRESSIN; ORAL CONTRACEPTIVE AGENT; RESPIRATORY TRACT AGENT; SODIUM; ARGIPRESSIN[1 DEAMINO];

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING DISORDER; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLUID BALANCE; HEMATOCRIT; HOT FLUSH; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SCHOOL CHILD; SELF REPORT; SERUM OSMOLALITY; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT RESPONSE; URINE OSMOLALITY; VITAL SIGN; VON WILLEBRAND DISEASE; WEIGHT CHANGE; BLOOD COAGULATION DISORDERS; CLINICAL TRIAL; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD COAGULATION DISORDERS; CHILD; CHILD, PRESCHOOL; DEAMINO ARGININE VASOPRESSIN; FEMALE; HUMANS; MALE; MIDDLE AGED; SELF REPORT; YOUNG ADULT;

EID: 84959044236     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12732     Document Type: Article

References (38)

1. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90: 2515-21.
2. Colucci G, Stutz M, Rochat S et al. The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects. Blood 2014; 123: 1905-16.
3. Lethagen S, Frick K, Sterner G. Antidiuretic effect of desmopressin given in hemostatic dosages to healthy volunteers. Am J Hematol 1998; 57: 153-9.
4. Miesbach W, Krekeler S, Duck O et al. Clinical assessment of efficacy and safety of DDAVP. Hamostaseologie 2010; 30(Suppl 1): S172-5.
5. Dunn AL, Cox Gill J. Adenotonsillectomy in patients with desmopressin responsive mild bleeding disorders: a review of the literature. Haemophilia 2010; 16: 711-6.
6. Di Perna C, Riccardi F, Franchini M, Rivolta GF, Pattacini C, Tagliaferri A. Clinical efficacy and determinants of response to treatment with desmopressin in mild hemophilia a. Semin Thromb Hemost 2013; 39: 732-9.
7. Seary ME, Feldman D, Carcao MD. DDAVP responsiveness in children with mild or moderate haemophilia A correlates with age, endogenous FVIII: C level and with haemophilic genotype. Haemophilia 2012; 18: 50-5.
8. Crescenzi G, Landoni G, Biondi-Zoccai G et al. Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. Anesthesiology 2008; 109: 1063-76.
9. Eckhardt CL, van Velzen AS, Peters M et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 2013; 122: 1954-62.
10. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003; 1: 682-9.
11. Dunn AL, Powers JR, Ribeiro MJ, Rickles FR, Abshire TC. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia 2000; 6: 11-4.
12. Schreiber A, Kubitza S, Luft FC. A woman with postoperative hyponatremia related to desmopressin acetate. Am J Kidney Dis 2004; 44: e3-6.
13. de Wee EM, Ikram MK, Dippel DW, Leebeek FW. Transient focal cerebral ischaemia and bilateral pulmonary embolism after desmopressin treatment for von Willebrand's disease. Haemophilia 2008; 14: 1133-4.
14. Molnar Z, Farkas V, Nemes L, Reusz GS, Szabo AJ. Hyponatraemic seizures resulting from inadequate post-operative fluid intake following a single dose of desmopressin. Nephrol Dial Transplant 2005; 20: 2265-7.
15. Olowokure O, Fishman M, Cromwell C, Aledort L. DDAVP for von Willebrand menorrhagia-severe hyponatraemia, haemolysis, seizure, coma.!! Caution. Haemophilia 2009; 15: 837.
16. Posthouwer D, Rommes JH, Van Bemmel TJ, Schaar CG. Severe hyponatraemia after DDAVP stimulation test in an adult patient. Haemophilia 2008; 14: 844-5.
17. Shah SN, Tran HA, Assal A, Ascunce RR, Yatskar L, Berger JS. In-stent thrombosis following DDAVP administration: case report and review of the literature. Blood Coagul Fibrinolysis 2014; 25: 81-3.
18. Bond L, Bevan D. Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 1988; 318: 121.
19. McLeod BC. Myocardial infarction in a blood donor after administration of desmopressin. Lancet 1990; 336: 1137-8.
20. Virtanen R, Kauppila M, Itala M. Percutaneous coronary intervention with stenting in a patient with haemophilia A and an acute myocardial infarction following a single dose of desmopressin. Thromb Haemost 2004; 92: 1154-6.
21. Achinger SG, Arieff AI, Kalantar-Zadeh K, Ayus JC. Desmopressin acetate (DDAVP)-associated hyponatremia and brain damage: a case series. Nephrol Dial Transplant 2014; 29: 2310-5.
22. Sharma R, Stein D. Hyponatremia after desmopressin (DDAVP) use in pediatric patients with bleeding disorders undergoing surgeries. J Pediatr Hematol Oncol 2014; 36: e371-5.
23. Nolan B, White B, Smith J, O'Reily C, Fitzpatrick B, Smith OP. Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders. Br J Haematol 2000; 109: 865-9.
24. Knofler R, Koscielny J, Tauer JT et al. Desmopressin testing in haemophilia A patients and carriers: results of a multi centre survey. Hamostaseologie 2012; 32: 271-5.
25. Leissinger C, Carcao M, Gill JC, Journeycake J, Singleton T, Valentino L. Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders. Haemophilia 2014; 20: 158-67.
26. Hartrick CT, Kovan JP, Shapiro S. The numeric rating scale for clinical pain measurement: a ratio measure? Pain Pract 2003; 3: 310-6.
27. Svensson PJ, Bergqvist PB, Juul KV, Berntorp E. Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. Blood Rev 2014; 28: 95-102.
28. Al-Salman J, Kemp D, Randall D. Hyponatremia. West J Med 2002; 176: 173-6.
29. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
30. Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost 1996; 76: 692-6.
31. Leissinger C, Becton D, Cornell C Jr, Cox Gill J. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 2001; 7: 258-66.
32. Verrua E, Mantovani G, Ferrante E et al. Severe water intoxication secondary to the concomitant intake of non-steroidal anti-inflammatory drugs and desmopressin: a case report and review of the literature. Hormones (Athens) 2013; 12: 135-41.
33. Wilmot B, Voruganti VS, Chang YP et al. Heritability of serum sodium concentration: evidence for sex- and ethnic-specific effects. Physiol Genomics 2012; 44: 220-8.
34. Juul KV, Klein BM, Sandstrom R, Erichsen L, Norgaard JP. Gender difference in antidiuretic response to desmopressin. Am J Physiol Renal Physiol 2011; 300: F1116-22.
35. Siew DA, Mangel J, Laudenbach L, Schembri S, Minuk L. Desmopressin responsiveness at a capped dose of 15 mug in type 1 von Willebrand disease and mild hemophilia A. Blood Coagul Fibrinol 2014; 25: 820-3.
36. Association of Hemophilia Clinic Directors of Canada. Management. Hemophilia and von Willebrand's Disease Clinical Practice Guidelines. Toronto, ON. http://ahcdc.ca/index.php/membership/practice-guidelines/86-hemophilia-and-vwd-clinical-practice-guidelines-management#Desmopressin Acetate. Accessed February 2, 2015.
37. Lethagen S, Harris AS, Sjorin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost 1987; 58: 1033-6.
38. Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med 1991; 114: 563-8.